Cellular therapies in systemic lupus erythematosus: recent progress and future directions.
CAR-T cell therapy shows potential for severe lupus unresponsive to standard treatment, though careful trials remain essential for safety and long-term success.
This review summarizes the immunopathogenic rationale and emerging clinical evidence for CAR-T cell therapy in SLE, highlighting CD19-directed approaches as potentially transformative for refractory disease. The review discusses open challenges including manufacturing, safety considerations, and long-term immune reconstitution, noting that well-designed trials are needed before routine use.
What the study was
- Study design
- Narrative review
- Population
- Patients with refractory systemic lupus erythematosus
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Clinical Rheumatology
Why it surfaced
Review of CAR-T in SLE captures an important cross-cutting signal: cellular therapy moving from hematologic malignancies to autoimmune disease. Relevant to both CAR-T and rare/refractory disease watchlist topics. Score capped by review design (no new primary data).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.